2A Pharma is a Swedish/Danish biopharmaceuticals company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented vaccine platform.
Our lead vaccine candidate, 2AP07, is a therapeutic cancer vaccine targeting adenocarcinomas expressing EpCAM.
Our vaccine technology is based on adeno-associated virus-like particles (AAVLPs), that assemble viral capsids without containing viral genomes; hence they are replicative-defective and non-pathogenic. The viral capsid has repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, generating an immune response where both the innate and the adaptive immune system are activated. In other words, 2A Pharma exploit the efficacy of the individuals’ own immune system to generate AAVLP-based vaccines that, without the addition of adjuvants, are able to develop highly effective antibodies with selected specificities and functions. The technology enables the production of highly efficient vaccines with significant competitive advantages.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Södergatan 3, Malmö,211 34,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- 2apharma.com
- HQ
- Malmö
2a Pharma Questions
2A Pharma's website is 2apharma.com
2A Pharma's LinkedIn profile is https://dk.linkedin.com/company/2a-pharma-ab
2A Pharma has
10 employees.
View email and phone details for 10
employees at 2A Pharma.
2A Pharma's industry is
Pharmaceutical Manufacturing
2A Pharma's top competitors are
Biogenity,
Aax Biotech Ab,
Nextcell Pharma Ab,
Ascelia Pharma Ab,
Gabather,
2n Pharma,
2care4 Group,
Abera Bioscience Ab,
Zealand Pharma,
Nmd Pharma A/s.
2A Pharma's categories are Pharmaceutical Manufacturing
2A Pharma's founding year is 2016
